Beyond Air Inc Stock Price, News & Analysis

Beyond Cancer, an affiliate of Beyond Air (NASDAQ: XAIR), announced promising data on its gaseous nitric oxide (gNO) therapy for solid tumors. Presenting at the AACR Annual Meeting 2022, studies showed gNO induced immune cell recruitment and reduced suppressor cells, indicating a potential anti-tumor response. The in vivo study observed increased immune cells and reduced suppression in treated mice, while the in vitro results indicated a dose-dependent cytotoxic effect across several cancer cell lines. A first-in-human study is expected to begin in Q2 2022.

Beyond Air, a clinical-stage company specializing in nitric oxide therapies, announced two important presentations at the AACR Annual Meeting, set for April 8-13, 2022, in New Orleans. They will showcase research on nitric oxide's impact on cancer treatments, particularly a study demonstrating a single injection's ability to elicit an immune response in tumors and another analyzing its cytotoxic effects against various cancer cells. These advancements could change the landscape of therapies for respiratory conditions and solid tumors.

Beyond Air, Inc. (NASDAQ: XAIR) announced its financial results for Q3 FY2021, reporting no revenue compared to $0.1 million last year and a net loss of $8 million. They are progressing with the LungFit® PH PMA submission to the U.S. FDA, aiming for approval in H1 2022. The company raised $30 million for its oncology affiliate, Beyond Cancer, retaining 80% equity. Research and development expenses decreased, but general and administrative expenses rose to $4.9 million. Upcoming milestones include data presentations and patient enrollment for key clinical studies scheduled in 2022.

Beyond Air, a clinical-stage medical device and biopharmaceutical company, announced that its CEO, Steve Lisi, will participate in two investor conferences in March 2022. The first event is the 34th Annual Roth Conference from March 13-15, 2022 in Dana Point, California. The second is the Oppenheimer 32nd Annual Healthcare Conference, with a virtual presentation scheduled for March 16, 2022 at 10:00 AM ET. Beyond Air focuses on developing inhaled nitric oxide for respiratory conditions and ultra-high concentration nitric oxide for solid tumors.

Beyond Air, Inc. (NASDAQ: XAIR) has appointed Mr. David Dvorak and Dr. Gregory Berk to the Board of Directors of its affiliate, Beyond Cancer. Dvorak, with over 25 years in healthcare leadership, previously served as CEO of Zimmer Biomet, overseeing significant revenue growth from $1.2 billion to $7.7 billion. Berk brings over 30 years of oncology expertise and currently leads R&D at GT Biopharma. These appointments aim to enhance Beyond Cancer's strategic execution and expedite its ultra-high concentration nitric oxide therapy for solid tumors, with first human studies expected in the first half of this year.

Beyond Air, Inc. (NASDAQ: XAIR) will report its third fiscal quarter financial results, ending December 31, 2021, on February 10, 2022. A conference call is scheduled at 4:30 PM ET for management to discuss results and future developments. The company focuses on inhaled nitric oxide technology for treating respiratory diseases and is progressing its LungFit® system for clinical trials targeting severe lung infections, including COVID-19. For further details, visit www.beyondair.net.

Beyond Air (NASDAQ: XAIR) announced a delay in the U.S. commercial launch of LungFit^® PH for persistent pulmonary hypertension of the newborn (PPHN), which will not occur before December 31, 2021. The company anticipates receiving CE Mark approval in Europe for LungFit^® PH within the first half of 2022. Beyond Air is committed to advancing its nitric oxide delivery system for treating serious respiratory conditions and solid tumors, showcasing its dedication to regulatory collaboration and innovation in pediatric care.

Beyond Air (NASDAQ: XAIR) has appointed Dr. Andrew Colin as Chief Medical Officer effective December 1, 2021. Dr. Colin, with four decades in pediatric pulmonology, has been a key member of Beyond Air’s Scientific Advisory Board since 2013. His extensive experience includes over 20 clinical trials and contributions to various pulmonology advancements. The company is focused on developing inhaled nitric oxide therapies for respiratory conditions and solid tumors. The leadership change is expected to enhance the growth of clinical programs, particularly in acute viral infections and nontuberculous mycobacteria.

Beyond Air has secured $30 million in a private placement of common shares for its affiliate, Beyond Cancer, giving investors a 20% equity stake. This funding will be utilized to accelerate preclinical studies, hire additional team members, and optimize the delivery system for nitric oxide treatments. Beyond Air retains 80% equity ownership in Beyond Cancer. The transaction, expected to close this quarter, aligns with Beyond Air's goal to develop inhaled nitric oxide therapies for pulmonary and cancer-related conditions. The shares are being offered under exemption from registration requirements.